The first prospective, randomized, controlled trial comparing the intravitreal anti-VEGF bevacizumab to conventional laser therapy reported an increased efficacy of anti-VEGF as compared with laser therapy for stage 3 plus ROP, but only in Zone I (Mintz-Hittner et al., 2011). This evidence concerns the gene VEGFA and retinopathy of prematurity.